Literature DB >> 33650932

Changes in epidemiological characteristics and sero-prevalence against the varicella zoster virus in school-age children after the introduction of a national immunization program in Japan.

Yosuke Yasui1,2, Toshikatsu Mitsui1, Fujiyo Arima1, Keiko Uchida1, Mikako Inokuchi1, Mitsuaki Tokumura1, Tetsuo Nakayama2.   

Abstract

A national immunization program using two doses of live attenuated varicella vaccine was introduced for children aged one to two years in Japan in October 2014. Varicella cases declined after 2014, and immunological status against varicella among vaccinated children changed in post-vaccination era. A retrospective observational study of anti-varicella antibody seroprevalence, varicella vaccination status, and history of varicella among 528 students in the first grade of elementary school was conducted. The percentage of students who received at least a single dose of varicella vaccination increased from 67% (187 of 279 students) in 2007-2008 to 91% (226 of 249 students) in 2017. Students with a history of varicella decreased from 114 of 279 (41%) in 2007-2008 to 48 of 249 (19%, P < .01) in 2017. Among them, the rate of breakthrough varicella after a single dose of vaccine in students with a history of varicella significantly increased from 38% (43 of 114 students) in 2007-2008 to 58% (28 of 48 students) in 2017 (P < .05). The antibody-positive rate significantly decreased from 50% among subjects without varicella zoster who received a single dose (95%CI: 41-58%) in 2007-2008 to 29% (95%CI: 21-38%) in 2017 (P < .01). The antibody-positive rate among students without varicella history who received two doses of vaccine was only 43% (95%CI: 32-55%) in 2017. The number of varicella infections and antibody-positive rate among students without history of varicella who received varicella vaccination decreased after the introduction of a national immunization program.

Entities:  

Keywords:  Varicella; elementary school students; epidemiology; immunization program; sero-prevalence

Mesh:

Substances:

Year:  2021        PMID: 33650932      PMCID: PMC8475580          DOI: 10.1080/21645515.2021.1890968

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  30 in total

1.  Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic.

Authors:  T Ozaki; N Nishimura; Y Kajita
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

2.  Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.

Authors:  B Ludwig; F B Kraus; R Allwinn; S Keim; H W Doerr; S Buxbaum
Journal:  Infection       Date:  2006-08       Impact factor: 3.553

3.  Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine.

Authors:  L Zerboni; S Nader; K Aoki; A M Arvin
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

4.  Estimation of age-specific rates of reactivation and immune boosting of the varicella zoster virus.

Authors:  Isabella Marinelli; Alies van Lier; Hester de Melker; Andrea Pugliese; Michiel van Boven
Journal:  Epidemics       Date:  2016-11-22       Impact factor: 4.396

5.  Varicella Outbreak Surveillance in Schools in Sentinel Jurisdictions, 2012-2015.

Authors:  Adriana S Lopez; Bethany LaClair; Vicki Buttery; Yufang Zhang; Jennifer Rosen; Elizabeth Taggert; Sara Robinson; Mychal Davis; Catherine Waters; Carrie A Thomas; Carmen Rodriguez; Ebony Thomas; Jessica Tuttle; Tamara Brantley; Dana Perella; Maria Del Rosario; Mona Marin
Journal:  J Pediatric Infect Dis Soc       Date:  2019-05-11       Impact factor: 3.164

6.  Changing varicella epidemiology in active surveillance sites--United States, 1995-2005.

Authors:  Dalya Guris; Aisha O Jumaan; Laurene Mascola; Barbara M Watson; John X Zhang; Sandra S Chaves; Paul Gargiullo; Dana Perella; Rachel Civen; Jane F Seward
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

7.  The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox.

Authors:  A A Gershon; P LaRussa; S Steinberg; N Mervish; S H Lo; P Meier
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

8.  Two-dose varicella vaccine effectiveness and rash severity in outbreaks of varicella among public school students.

Authors:  Carrie A Thomas; Thein Shwe; Dee Bixler; Maria del Rosario; Scott Grytdal; Chengbin Wang; Loretta E Haddy; Stephanie R Bialek
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

9.  Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015.

Authors:  Thorsten Rieck; Marcel Feig; Matthias An der Heiden; Anette Siedler; Ole Wichmann
Journal:  Euro Surveill       Date:  2017-04-27

Review 10.  Global Varicella Vaccine Effectiveness: A Meta-analysis.

Authors:  Mona Marin; Melanie Marti; Anita Kambhampati; Stanley M Jeram; Jane F Seward
Journal:  Pediatrics       Date:  2016-02-16       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.